Abstract
In vitro cytochrome P450 (CYP) inhibition assays are common approaches for testing the inhibition potential of drugs for predicting potential interactions. In contrast to marketed medicaments, drugs of abuse, particularly the so-called novel psychoactive substances, were not tested before distribution and consumption. Therefore, the inhibition potential of methylenedioxy-derived designer drugs (MDD) of different drug classes such as aminoindanes, amphetamines, benzofurans, cathinones, piperazines, pyrrolidinophenones, and tryptamines should be elucidated. The FDA-preferred test substrates, split in two cocktails, were incubated with pooled human liver microsomes and analysed after protein precipitation using LC-high-resolution-MS/MS. IC50 values were determined of MDD showing more than 50 % inhibition in the prescreening. Values were calculated by plotting the relative metabolite concentration formed over the logarithm of the inhibitor concentration. All MDD showed inhibition against CYP2D6 activity and most of them in the range of the clinically relevant CYP2D6 inhibitors quinidine and fluoxetine. In addition, the beta-keto compounds showed inhibition of the activity of CYP2B6, 5,6-MD-DALT of CYP1A2 and CYP3A, and MDAI of CYP2A6, all in the range of clinically relevant inhibitors. In summary, all MDD showed inhibition of the activity of CYP2D6, six of CYP1A2, three of CYP2A6, 13 of CYP2B6, two of CYP2C9, six of CYP2C19, one of CYP2E1, and six of CYP3A. These results showed that the CYP inhibition by MDD might be clinically relevant, but further studies are needed for final conclusions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Advisory Council on the Misuse of Drugs (ACMD) (2013) Benzofurans: a review of the evidence of use and harm. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/261783/Benzofuran_compounds_report.pdf
Baranczewski P, Stanczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H (2006) Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 58:453–472
Bertelsen KM, Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289–293
Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211–1214
Burt HJ, Galetin A, Houston JB (2010) IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4. Xenobiotica 40:331–343
Carter N, Rutty GN, Milroy CM, Forrest AR (2000) Deaths associated with MBDB misuse. Int J Legal Med 113:168–170
Coppola M, Mondola R (2012) 3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208:12–15
Corkery JM, Elliott S, Schifano F, Corazza O, Ghodse AH (2013) MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’) toxicity: a brief overview and update. Hum Psychopharmacol 28:345–355
Dinger J, Meyer MR, Maurer HH (2014a) Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail. Anal Bioanal Chem 406:4453–4464
Dinger J, Meyer MR, Maurer HH (2014b) Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicol Lett 230:28–35
Elliott S, Evans J (2014) A 3-year review of new psychoactive substances in casework. Forensic Sci Int 243C:55–60
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2014a) European drug report: trends and developments. http://www.emcdda.europa.eu/attachements.cfm/att_228272_EN_TDAT14001ENN.pdf
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2014b) Report on the risk assessment of 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV) in the framework of the Council Decision on new psychoactive substances. http://www.emcdda.europa.eu/attachements.cfm/att_228256_EN_MDPV%20RAR_with%20annexes.pdf
Ewald AH, Maurer HH (2008) 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6. Toxicol Lett 183:52–57
Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827–2831
Gebhardt AC, Lucas D, Menez JF, Seitz HK (1997) Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology 26:957–961
Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P (2008) Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol (Phila) 46:802–807
Gee P, Jerram T, Bowie D (2010) Multiorgan failure from 1-benzylpiperazine ingestion-legal high or lethal high? Clin Toxicol (Phila) 48:230–233
Hafner V, Albermann N, Haefeli WE, Ebinger F (2008) Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis. Antimicrob Agents Chemother 52:4172–4174
Heydari A, Yeo KR, Lennard MS, Ellis SW, Tucker GT, Rostami-Hodjegan A (2004) Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos 32:1213–1217
Kandavar R, Sander GE (2010) Atorvastatin induced multiple organ failure. J La State Med Soc 162:159–160
Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, Shin JG (2005) High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651–2658
Kobayashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T, Kuroiwa Y (1998) Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol 45:361–368
Koup JR, Gibaldi M, McNamara P, Hilligoss DM, Colburn WA, Bruck E (1978) Interaction of chloramphenicol with phenytoin and phenobarbital. Case report. Clin Pharmacol Ther 24:571–575
Kraemer T, Maurer HH (2002) Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives [review]. Ther Drug Monit 24:277–289
Lu C (2014) Metabolic stability screen in drug discovery. In: Lee PW, Aizawa H, Gan LL, Prakash C (eds) Handbook of metabolic pathways of xenobiotics. Wiley, New York, pp 499–521
Niwa T, Shiraga T, Takagi A (2005) Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28:1805–1808
Palleria C, Di PA, Giofre C, Caglioti C, Leuzzi G, Siniscalchi A, De SG, Gallelli L (2013) Pharmacokinetic drug–drug interaction and their implication in clinical management. J Res Med Sci 18:601–610
Park JY, Kim KA, Kim SL (2003) Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother 47:3464–3469
Pearson JM, Hargraves TL, Hair LS, Massucci CJ, Frazee CC III, Garg U, Pietak BR (2012) Three fatal intoxications due to methylone. J Anal Toxicol 36:444–451
Pedersen AJ, Petersen TH, Linnet K (2013) In vitro metabolism and pharmacokinetic studies on methylone. Drug Metab Dispos 41:1247–1255
Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH (2003) Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J Mass Spectrom 38:659–676
Pritzker D, Kanungo A, Kilicarslan T, Tyndale RF, Sellers EM (2002) Designer drugs that are potent inhibitors of CYP2D6. J Clin Psychopharmacol 22:330–332
Roy PP, Roy K (2010) Pharmacophore mapping, molecular docking and QSAR studies of structurally diverse compounds as CYP2B6 inhibitors. Mol Simul 36:887–905
Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A (2012) Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care 16:R136
Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F (2007) Concentrations of Tramadol and O-desmethyltramadol Enantiomers in Different CYP2D6 Genotypes. Clin Pharmacol Ther 82:41–47
Stanczuk A, Morris N, Gardner EA, Kavanagh P (2013) Identification of (2-aminopropyl)benzofuran (APB) phenyl ring positional isomers in internet purchased products. Drug Test Anal 5:270–276
Tanaka E, Kamata T, Katagi M, Tsuchihashi H, Honda K (2006) A fatal poisoning with 5-methoxy-N, N-diisopropyltryptamine, Foxy. Forensic Sci Int 163:152–154
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2006) Guidance for industry: drug interaction studies—study design, data analysis, and implications for dosing and labeling [Draft]
von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI (1998) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 38:106–111
Wilson JM, McGeorge F, Smolinske S, Meatherall R (2005) A foxy intoxication. Forensic Sci Int 148:31–36
Wu D, Otton SV, Inaba T, Kalow W, Sellers EM (1997) Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 53:1605–1612
Xu C, Desta Z (2013) In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug Metab Pharmacokinet 28:362–371
Acknowledgments
The authors like to thank their colleagues Simon Brandt, Achim Caspar, Giselher Fritschi, Andreas G. Helfer, Julian A. Michely, Pierce Kavanagh, Peter Rösner Armin A. Weber, Jessica Welter, Folker Westphal, and Carina S.D. Wink for their support.
Conflict of interest
The authors declare that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dinger, J., Meyer, M.R. & Maurer, H.H. In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach. Arch Toxicol 90, 305–318 (2016). https://doi.org/10.1007/s00204-014-1412-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-014-1412-6